Figures & data
Figure 1 Study design of the RAPID-RCT and RAPID-OLE trials employing lung density measures by CT scans at 0, 3, 12, 21, 24, 36 and 48 months.
![Figure 1 Study design of the RAPID-RCT and RAPID-OLE trials employing lung density measures by CT scans at 0, 3, 12, 21, 24, 36 and 48 months.](/cms/asset/55e7484a-4787-4a69-aaa2-97b43c65df96/dcop_a_149429_f0001_b.jpg)
Figure 2 Annualized rate of decline in physiologically adjusted P15 lung density (g/L) at TLC over 48 months.
Abbreviations: AAT, alpha 1 antitrypsin; adjusted P15, lung volume-adjusted 15th percentile of the lung density; OLE, open-label extension; RAPID, Randomized, Placebo-controlled Trial of Augmentation Therapy in Alpha-1 Proteinase Inhibitor Deficiency; RCT, randomized controlled trial; TLC, total lung capacity.
![Figure 2 Annualized rate of decline in physiologically adjusted P15 lung density (g/L) at TLC over 48 months.](/cms/asset/5aee5b79-c4ab-4df2-9dd4-01c591d9be53/dcop_a_149429_f0002_b.jpg)
Table 1 Characteristics of clinical trials and observational studies using CT densitometric indices as outcome measures for emphysema progression
Figure 3 Change in clinical outcome measures after administration of a disease-modifying therapy.
Notes: Reproduced with permission from Taylor & Francis. The Version of Scholarly Record of this Article is published in COPD: Journal of Chronic Obstructive Pulmonary Disease (2016), available online at: http://www.tandfonline.com/10.1080/15412555.2016.1178224. This article was distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives license. Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chorostowska-Wynimko J, Vol 13, pp. 807–815, published online: 12 May 2016, http://www.tandfonline.com reprinted by permission of the publisher.Citation23
![Figure 3 Change in clinical outcome measures after administration of a disease-modifying therapy.Notes: Reproduced with permission from Taylor & Francis. The Version of Scholarly Record of this Article is published in COPD: Journal of Chronic Obstructive Pulmonary Disease (2016), available online at: http://www.tandfonline.com/10.1080/15412555.2016.1178224. This article was distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives license. Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chorostowska-Wynimko J, Vol 13, pp. 807–815, published online: 12 May 2016, http://www.tandfonline.com reprinted by permission of the publisher.Citation23](/cms/asset/94b1e3bd-ade8-4ba3-ba88-4487a786fa5a/dcop_a_149429_f0003_b.jpg)
Figure 4 Extrapolation of the effect of AAT replacement therapy on the predicted time to reach terminal respiratory function in RAPID-RCT.
Abbreviations: AAT, alpha 1 antitrypsin; RAPID, Randomized, Placebo-controlled Trial of Augmentation Therapy in Alpha-1 Proteinase Inhibitor Deficiency; RCT, randomized controlled trial.
![Figure 4 Extrapolation of the effect of AAT replacement therapy on the predicted time to reach terminal respiratory function in RAPID-RCT.](/cms/asset/b83e79d4-d245-477e-8989-0a1e95a63703/dcop_a_149429_f0004_b.jpg)
Figure 5 ACSM exercise recommendations for pulmonary rehabilitation.Citation90
![Figure 5 ACSM exercise recommendations for pulmonary rehabilitation.Citation90](/cms/asset/cd76ce22-1da9-40ea-a903-dc163930698d/dcop_a_149429_f0005_b.jpg)